Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on September 9, 2019. The registrant is a Delaware corporation with principal executive offices in Alameda, California, and its common stock trades on the NYSE American under the symbol AGE. The filing serves as a Regulation FD disclosure regarding an upcoming presentation at the 21st Annual Rodman & Renshaw Global Investment Conference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a conference presentation and does not contain financial statements or operational data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely announces the intent to present information contained in an attached slide deck (Exhibit 99.1) to investors.
Guidance, Outlook, and Risks
- Event: CEO Michael D. West, Ph.D., is scheduled to present at the Rodman & Renshaw Global Investment Conference in New York City on September 9, 2019, at 8:20 a.m. EDT.
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking. Actual results may differ materially due to risks detailed in the company's Form 10-K and 10-Q filings.
- Legal Status: The report and Exhibit 99.1 are deemed "furnished" rather than "filed" under the Exchange Act and are not subject to Section 18 liability unless expressly incorporated by reference.
Investor Verification Checklist
- Verify the company name is AgeX Therapeutics, Inc. (Ticker: AGE), as the input metadata incorrectly referenced "Serina Therapeutics."
- Review Exhibit 99.1 (the slide presentation) for the actual business updates and data referenced in this filing.
- Consult the most recent Form 10-K and 10-Q for detailed financial metrics, risk factors, and historical performance, as this 8-K contains none.
- Confirm the presentation date and time (September 9, 2019, 8:20 a.m. EDT) if seeking historical context on investor communications.